FDA Revokes Marketing Denial Order for JUUL E-cigarettes

Regulations by 2FIRSTS.ai
Jun.07.2024
FDA Revokes Marketing Denial Order for JUUL E-cigarettes
FDA lifts sales refusal order on JUUL, returning application to pending status after first-ever Marketing Denial Order revocation.

Editor's note: On June 6, local time, the US FDA announced the voluntary withdrawal of the Marketing Denial Order (MDO) for JUUL, allowing the application to return to pending status. This is reportedly the first time the FDA has voluntarily withdrawn a Marketing Denial Order (MDO).

 

On June 6th, the Food and Drug Administration (FDA) of the United States released a press release announcing updates on its review of the Premarket Tobacco Product Applications (PMTAs) submitted by JUUL Labs, Inc.

 

On June 23, 2022, the FDA issued Marketing Denial Orders (MDOs) for all products of JUUL Labs, Inc. that were being sold in the United States at the time. The FDA determined that these applications lacked sufficient evidence regarding the toxic characteristics of the products, and failed to demonstrate that the marketing of the products met the public health standards required by law. When announcing the issuance of the MDOs, the FDA stated that insufficient and conflicting data on genotoxicity and potential harmful chemicals leaching from the company's proprietary pods prevented the agency from completing a comprehensive toxicological review of the products.

 

On July 5, 2022, the FDA administratively suspended MDOs (medical device orders) after determining that certain scientific issues required additional review. Since then, the FDA has conducted additional reviews and substantial reviews in multiple areas, including toxicology, engineering, social sciences, and clinical pharmacology.

 

Meanwhile, since the administrative pause of MDOs in 2022, the FDA has gained more experience in various scientific issues related to e-cigarette products and has seen new litigation outcomes in MDOs cases involving other manufacturers' e-cigarette products. Some of these court rulings have established new precedents and provided information for the FDA's product review methods to uphold its commitment to making appropriate final decisions based on science and law.

 

Today, on June 6th, the FDA revoked the MDOs issued to JUUL Labs, Inc. in June 2022. This action was partly due to new legal precedents and FDA's review of information provided by the applicant. Revoking the MDOs is neither an authorization nor a denial, and does not indicate whether the application is likely to be authorized or denied. Revoking the MDOs returns the application to a pending status for substantive review by the FDA. FDA regulations severely limit the information the agency can disclose about pending applications.

 

Once accepted and filed by the FDA, applications under review will ultimately receive either a sale permit or a sale rejection order. Additional steps may be taken temporarily during any application review, as stated on the FDA website.

 

The FDA's ongoing review does not change the fact that, according to the law, all e-cigarette products, including those made by JUUL, must obtain FDA authorization to legally market them.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Azerbaijan's sweeping e-cigarette ban has raised concerns over enforcement errors and the emergence of illicit sales, while neighboring Armenia is tightening technical rules and preparing higher excise taxes. Georgia, meanwhile, has resisted calls for broader vape restrictions and introduced preferential taxes for some domestically produced cigarettes. The divergent approaches across the South Caucasus highlight a regional policy dilemma: how to curb nicotine use and protect public health without encouraging black markets or creating unintended economic consequences for businesses and consumers.
Nov.03
Italy Proposes Earlier Vape and HTP Tax Hikes, New Rules for E-Liquid Pricing, Exclusive Deals and Distribution
Italy Proposes Earlier Vape and HTP Tax Hikes, New Rules for E-Liquid Pricing, Exclusive Deals and Distribution
Italy's proposed 2027–2029 budget would bring forward scheduled tax increases for e-cigarette liquids and heated tobacco products from January 1, 2028, to July 1, 2027. The consumption tax coefficient for nicotine-containing e-liquids would rise from 20% to 22%, that for nicotine-free liquids and applicable flavorings from 15% to 17%, and the heated-tobacco coefficient from 41% to 42%. The bill would also introduce official retail price schedules for e-liquids, restrict exclusive agreements between retailers and suppliers, and limit single-brand-dominated displays, sales incentives and bundled offers. Importing, authorized warehousing and retailer sourcing arrangements would also change. The proposals remain subject to parliamentary approval and subsequent implementing regulations.
Regulations
Nov.04